Randox

Randox Laboratories, headquartered in the UK, is a global leader in diagnostics and biomarker solutions with 60,000 end users in 130 countries.  Through their Pharma Services Division, Randox’s Biochip Array Technology, a single platform enabling both protein and nucleic acid multiplex analysis, has been adopted by major pharma and global CRO’s to support clinical trials.  Due its unrivalled package of sensitivity, precision and reproducibility, it is considered the multiplex platform of choice.  The fully automated ‘Evidence’ Biochip analyzer is an FDA 510K approved system, with FDA and CE marked immunoassay arrays available; all developed in-house at Randox’s FDA inspected, ISO 13485 accredited manufacturing facilities. 

For DNA/RNA multiplexing applications, recently released arrays include:

• A 22-plex Respiratory Pathogen Array for rapid viral and bacterial pathogen detection; and 
• A 20-plex oncology array detecting key mutations in KRAS/BRAF/ PIK3CA.

All from a single tube, Randox’s highly sensitive multiplex PCR assay provides time, sample, and cost savings over current methods.

Additional Protein, mRNA, and genetic analysis panels are available for:

• Oncology;
• Metabolic;
• Inflammation/Immune;
• Cardiovascular; and
• Neurobiology therapeutic areas.   

Randox has over 4,500 labs using their instrumentation and strong regulatory expertise with over 400 FDA approved and 850 CE marked tests, ensuring Randox is ideally placed to support drug development with cutting edge diagnostic and biomarker solutions.

www.randox.com